Syndax Pharmaceuticals (SNDX) Enterprise Value: 2015-2025
Historic Enterprise Value for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Sep 2025 value amounting to $889.3 million.
- Syndax Pharmaceuticals' Enterprise Value fell 28.77% to $889.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$651.0 million, marking a year-over-year decrease of 257.94%. This contributed to the annual value of $555.5 million for FY2024, which is 40.53% down from last year.
- Latest data reveals that Syndax Pharmaceuticals reported Enterprise Value of $889.3 million as of Q3 2025, which was up 153.65% from $350.6 million recorded in Q2 2025.
- Syndax Pharmaceuticals' Enterprise Value's 5-year high stood at $1.6 billion during Q1 2024, with a 5-year trough of $350.6 million in Q2 2025.
- For the 3-year period, Syndax Pharmaceuticals' Enterprise Value averaged around $915.9 million, with its median value being $934.2 million (2023).
- Per our database at Business Quant, Syndax Pharmaceuticals' Enterprise Value spiked by 246.96% in 2021 and then slumped by 73.43% in 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Enterprise Value (Quarterly) stood at $859.0 million in 2021, then soared by 46.59% to $1.3 billion in 2022, then decreased by 25.81% to $934.2 million in 2023, then plummeted by 40.53% to $555.5 million in 2024, then declined by 28.77% to $889.3 million in 2025.
- Its last three reported values are $889.3 million in Q3 2025, $350.6 million for Q2 2025, and $544.6 million during Q1 2025.